ABSTRACT
La hipertensión arterial (HTA) es una dolencia frecuente en los pacientes con neoplasias oncohematológicas activas o supervivientes a estas. Se estima que la prevalencia de HTA en esta población oscila entre el 30 y el 70%. La relación entre cáncer e HTA es multifactorial: factores de riesgo comunes, neoplasias que producen HTA a través de la secreción hormonal y, especialmente, fármacos quimioterápicos que producen HTA. La monitorización ambulatoria de presión arterial (MAPA) es una herramienta fundamental en el diagnóstico y adecuado control de la presión arterial, evitando tener que suspender o disminuir la dosis de tratamiento quimioterápico. Además, puede ayudar en el diagnóstico de la disfunción autonómica relacionada con ciertas enfermedades neoplásicas. (AU)
Hypertension (HT) is a frequent pathology in patients with active or surviving onco-haematological malignancies. It is estimated that the prevalence of HT in this population ranges between 30 and 70%. The relationship between cancer and HT is multifactorial: common risk factors, neoplasia that cause HT through hormonal secretion, and, especially, chemotherapy drugs that cause HT. Ambulatory blood pressure monitoring (ABPM) is a fundamental tool in the diagnosis and adequate control of blood pressure, avoiding having to suspend or reduce the dose of chemotherapy treatment. In addition, it can help in the diagnosis of autonomic dysfunction related to certain neoplastic pathologies. (AU)
Subject(s)
Humans , Hypertension/epidemiology , Neoplasms , Medical Oncology , Blood Pressure Monitoring, Ambulatory , Hypertension/diagnosis , Hypertension/prevention & control , Risk FactorsABSTRACT
Los inhibidores de la tirosinacinasa son una familia de fármacos quimioterápicos utilizados en primera y segunda línea de muchas neoplasias sólidas y hematológicas. Su toxicidad es relativamente baja, ya que el mecanismo de acción se fundamenta en la inhibición de algunas tirosinacinasas involucradas en la proliferación de las células neoplásicas. Sin embargo, este bloqueo no es selectivo, por lo que pueden producir efectos secundarios. Sorafenib se ha relacionado con la aparición de hipertensión arterial, alteraciones tiroideas, dolor abdominal o hiperamilasemia, entre otros. Deben conocerse los efectos secundarios de estos fármacos para una adecuada monitorización de los pacientes que evite la suspensión de estos agentes quimioterápicos. (AU)
Tyrosine kinase inhibitors are a family of chemotherapy drugs used in first and second line for many solid and hematological neoplasms. Its toxicity is relatively low, since the mechanism of action is based on the inhibition of some tyrosine kinases involved in the explosion of neoplastic cells. However, this blockade is not selective, so it can produce secondary effects. Sorafenib can produce arterial hypertension, thyroid disorders, abdominal pain or hyperamylasemia, among others. We must monitor these patients during treatment to avoid side effects. (AU)
Subject(s)
Humans , Male , Middle Aged , Sorafenib/poisoning , Sorafenib/therapeutic use , Protein Kinase Inhibitors , Sorafenib/adverse effects , Hypertension , Hypothyroidism , Drug-Related Side Effects and Adverse ReactionsABSTRACT
Hypertension (HT) is a frequent pathology in patients with active or surviving onco-haematological malignancies. It is estimated that the prevalence of HT in this population ranges between 30 and 70%. The relationship between cancer and HT is multifactorial: common risk factors, neoplasia that cause HT through hormonal secretion, and, especially, chemotherapy drugs that cause HT. Ambulatory blood pressure monitoring (ABPM) is a fundamental tool in the diagnosis and adequate control of blood pressure, avoiding having to suspend or reduce the dose of chemotherapy treatment. In addition, it can help in the diagnosis of autonomic dysfunction related to certain neoplastic pathologies.
Subject(s)
Hematologic Diseases , Hypertension , Humans , Blood Pressure Monitoring, Ambulatory , Hypertension/drug therapy , Blood Pressure , Risk FactorsABSTRACT
Tyrosine kinase inhibitors are a family of chemotherapy drugs used in first and second line for many solid and hematological neoplasms. Its toxicity is relatively low, since the mechanism of action is based on the inhibition of some tyrosine kinases involved in the explosion of neoplastic cells. However, this blockade is not selective, so it can produce secondary effects. Sorafenib can produce arterial hypertension, thyroid disorders, abdominal pain or hyperamylasemia, among others. We must monitor these patients during treatment to avoid side effects.
ABSTRACT
Secondary arterial hypertension (HTN) can be caused by primary hyperaldosteronism, renovascular disease, sleep apnea syndrome, chronic kidney disease, drug use, etc. In addition, some urological disorders such as hydronephrosis can cause hypertension due to an increase in intraglomerular pressure that activates the renin angiotensin system.(AU)
La hipertensión arterial (HTA) secundaria engloba un amplio diagnóstico diferencial que incluye causas tan distintas como el hiperaldosteronismo primario, la enfermedad renovascular, el síndrome de apnea del sueño, la enfermedad renal crónica, el consumo de fármacos, etc. Existen, además, ciertos trastornos urológicos como la hidronefrosis que pueden producir HTA debido a un aumento de presión intraglomerular que active el sistema renina-angiotensina.(AU)
Subject(s)
Humans , Female , Adult , Hypertension , Ureterocele , Hydronephrosis , HyperaldosteronismABSTRACT
Secondary arterial hypertension (HTN) can be caused by primary hyperaldosteronism, renovascular disease, sleep apnea syndrome, chronic kidney disease, drug use, etc. In addition, some urological disorders such as hydronephrosis can cause hypertension due to an increase in intraglomerular pressure that activates the renin angiotensin system.
Subject(s)
Hyperaldosteronism , Hypertension , Kidney Diseases , Female , Humans , Hyperaldosteronism/complications , Hypertension/complications , Middle Aged , Renin , Renin-Angiotensin SystemABSTRACT
La mejora de la supervivencia de los pacientes con cáncer ha llevado consigo un incremento en la aparición de enfermedad cardiovascular (ECV). Esto es debido al aumento de la edad de los sujetos y a los efectos secundarios de los agentes antineoplásicos. La aparición de hipertensión arterial (HTA) en los pacientes tratados con fármacos anti-angiogénicos es un efecto adverso común, que puede obligar a reducir la dosis de quimioterapia o incluso a suspenderla. Presentamos los casos de tres personas tratadas con distintos anti-angiogénicos, y que desarrollaron HTA secundaria. (AU)
Survival of neoplasms has improved significantly in recent years. An increase in the incidence of cardiovascular disease has been observed. This is due to increasing age of patients and the side effects of chemotherapy. Anti-angiogenic drugs frequently cause hypertension. This may force the reduction or suspension of chemotherapy treatment. We present the cases of three patients treated with different anti-angiogenic drugs. All three developed secondary arterial hypertension. (AU)
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Hypertension/chemically induced , Hypertension/drug therapy , Neoplasms/complications , Neoplasms/drug therapy , Cardiovascular Diseases , Angiogenesis Inhibitors/adverse effectsABSTRACT
Survival of neoplasms has improved significantly in recent years. An increase in the incidence of cardiovascular disease has been observed. This is due to increasing age of patients and the side effects of chemotherapy. Anti-angiogenic drugs frequently cause hypertension. This may force the reduction or suspension of chemotherapy treatment. We present the cases of three patients treated with different anti-angiogenic drugs. All three developed secondary arterial hypertension.
Subject(s)
Angiogenesis Inhibitors , Cardiovascular Diseases , Hypertension , Neoplasms , Angiogenesis Inhibitors/adverse effects , Humans , Hypertension/chemically induced , Hypertension/drug therapy , Neoplasms/complications , Neoplasms/drug therapyABSTRACT
La disfunción autonómica es una enfermedad muy frecuente en las alfa-sinucleoinopatías (enfermedad de Parkinson, demencia por cuerpos de Lewy, atrofia multisistémica). A nivel cardiovascular puede producir síntomas como hipotensión ortostática, hipertensión supina o disminución de la respuesta de la frecuencia cardiaca a estímulos. Para el diagnóstico es fundamental una sospecha clínica y una exploración física minuciosa, tomando la presión arterial tanto en posición de decúbito supino como en bipedestación. El electrocardiograma puede mostrar un alargamiento de los intervalos PR y QT, mientras que la monitorización ambulatoria de presión arterial de 24 h aporta información sobre los patrones de presión arterial. La confirmación de la disfunción simpática cardiaca puede realizarse con una gammagrafía miocárdica de inervación con 123-I-metilbencilguanidina (123-I-MIBG), ya que refleja la captación noradrenérgica neuronal específica. A continuación presentamos el caso de un varón con enfermedad de Parkinson que tras un completo estudio fue diagnosticado de disfunción autonómica cardiovascular
Autonomic dysfunction is a common condition in the alpha-synucleinopathies (Parkinson's disease, dementia with Lewy bodies, multiple system atrophy). Cardiovascular symptoms may include orthostatic hypotension, supine hypertension or decreased heart rate response. A clinical suspicion and physical examination are essential for diagnosis, taking blood pressure in supine and standing positions. The electrocardiogram may show a prolongation of the PR and QT intervals, while 24-hour ambulatory blood pressure monitoring provides information on blood pressure patterns. Cardiac sympathetic dysfunction can be confirmed by an innervation myocardial scintigraphy with 123-I-methylbenzylguanidine (123-I-MIBG). This can reflect specific neuronal noradrenergic uptake.We present the case of a man with Parkinson's disease who was diagnosed with cardiovascular autonomic dysfunction after a complete study
Subject(s)
Humans , Male , Aged, 80 and over , Autonomic Nervous System Diseases/complications , Autonomic Nervous System Diseases/diagnostic imaging , Neurodegenerative Diseases/complications , Arterial Pressure/drug effects , Autonomic Nervous System Diseases/physiopathology , Severity of Illness Index , Electrocardiography , Heart Rate , Captopril , Long QT Syndrome/diagnosisABSTRACT
Autonomic dysfunction is a common condition in the alpha-synucleinopathies (Parkinson's disease, dementia with Lewy bodies, multiple system atrophy). Cardiovascular symptoms may include orthostatic hypotension, supine hypertension or decreased heart rate response. A clinical suspicion and physical examination are essential for diagnosis, taking blood pressure in supine and standing positions. The electrocardiogram may show a prolongation of the PR and QT intervals, while 24-hour ambulatory blood pressure monitoring provides information on blood pressure patterns. Cardiac sympathetic dysfunction can be confirmed by an innervation myocardial scintigraphy with 123-I-methylbenzylguanidine (123-I-MIBG). This can reflect specific neuronal noradrenergic uptake. We present the case of a man with Parkinson's disease who was diagnosed with cardiovascular autonomic dysfunction after a complete study.
